Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13005210 | 0.77 | AKT1 (0.39) | SCN10A | |
| SCHEMBL10107980 | 0.76 | SCN10A (0.35) | SCN10AKCNH2 | |
| SCHEMBL10102633 | 0.76 | RPS6KB2 (0.40) | SCN10A | |
| SCHEMBL10102638 | 0.76 | GPBAR1 (0.42) | SCN10AKCNH2 | |
| SCHEMBL13005209 | 0.75 | SCN10A (0.34) | SCN10AKCNH2 | |
| SCHEMBL10102643 | 0.75 | SCN10A (0.34) | SCN10AKCNH2 | |
| SCHEMBL3386183 | 0.73 | PIK3CG (0.40) | SCN10A | |
| SCHEMBL10102655 | 0.72 | PDE4B (0.37) | — | |
| SCHEMBL13005260 | 0.71 | SCN10A (0.33) | SCN10AKCNH2 | |
| SCHEMBL13004730 | 0.70 | ERCC5 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207345-B2 | Antitumor agents; use in combination with other drugs such as pentamidine | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20080200451-A1 | Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 | MERCK PATENT GMBH (DE) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200451-A1 | Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 | KIF5A, KIF5C, KIF5B | SCN10A 2031/4885KCNH2 1709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.